Trials / Recruiting
RecruitingNCT05553236
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,500 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Targeted next-generation sequencing | During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee. |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2022-09-23
- Last updated
- 2026-01-26
Locations
1 site across 1 country: South Africa
Source: ClinicalTrials.gov record NCT05553236. Inclusion in this directory is not an endorsement.